66.99 0.00 (0.00%)
After hours: 6:36PM EDT
|Bid||66.66 x 800|
|Ask||66.99 x 900|
|Day's Range||66.70 - 68.08|
|52 Week Range||52.51 - 80.71|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||22.86|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zacks.com highlights: Manulife Financial, Jazz Pharmaceuticals, DaVita, American Axle & Manufacturing Holdings and Huntsman
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
The civil settlement with HealthCare Partners Holdings, which Denver-based DaVita acquired in 2012 and is in the process of selling to UnitedHealth Group Inc (:UNH.N), was announced on Monday by the U.S. Justice Department. HealthCare Partners did not admit wrongdoing.
Shares of dialysis clinic operator DaVita rose more than 3 percent on Monday after California's governor vetoed a bill that would have cut into its sales.
The bill, which was vetoed by Gov. Jerry Brown on Sunday, would have limited reimbursements for financial assistance to dialysis patients. Shares of dialysis clinic operator DaVita DVA rose more than 3 percent on Monday after California's governor vetoed a bill that would have cut into its sales.
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.
DaVita (DVA) reported revenues of ~$2.9 billion in the second quarter of 2018, which is a 6.9% YoY (year-over-year) growth compared to $2.7 billion in the second quarter of 2017. DaVita reported 6.9% growth in its top line to $2.89 billion, including an 11.1% growth in revenues from US dialysis and related lab services to $2.57 billion, offset by a 17.7% decrease in revenues for other ancillary services and strategic initiatives in the second quarter of 2018. Medicare and Medicare Advantage revenues were $1.5 billion in the second quarter of 2018, a 16.2% growth compared to $1.3 billion in the second quarter of 2017.
DaVita (DVA) is a biotechnology company focused on the discovery, development, and commercialization of specialist medicines to cater to the medical needs in rare diseases and other specialized conditions. DaVita reported non-GAAP EPS of $1.15 on revenues of $2.9 billion, a 6.9% growth YoY (year-over-year) compared to $2.7 billion in the second quarter of 2017.
Since DaVita Inc (NYSE:DVA) released its earnings in June 2018, analysts seem cautiously bearish, as a 8.6% rise in profits is expected in the upcoming year, against the higher pastRead More...
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DaVita (DVA) released its second-quarter earnings after the market closed on August 1. It surpassed Wall Street analysts’ estimates for revenues and EPS and reported non-GAAP EPS of $1.15 on revenues of $2.9 billion. The EPS estimate was $0.97 on revenues of $2.8 billion.
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 8.25% and 0.18%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
As discussed previously, analysts expect DaVita (DVA) to post revenue of $2.877 billion, adjusted net income of ~$175.97 million, and non-GAAP EPS of ~$0.97 in Q2 2018. Of the ten analysts tracking DaVita, five recommend “strong buy,” four recommend “hold,” and one recommends “sell.”
DaVita (DVA), which divides its business into two segments, DaVita Kidney Care and DaVita Medical Group, is set to release its Q2 2018 results tomorrow. Analysts expect it to post EPS of $0.97 on revenue of $2.8 billion. The chart below shows DaVita’s EPS and revenue since Q1 2017, as well as analysts’ Q2 2018 estimates.